comparemela.com

Latest Breaking News On - Dannyl dearen - Page 11 : comparemela.com

DexCom (NASDAQ:DXCM) and Axonics (NASDAQ:AXNX) Head-To-Head Survey

DexCom (NASDAQ:DXCM – Get Rating) and Axonics (NASDAQ:AXNX – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends. Analyst Recommendations This is a breakdown of recent ratings and price targets […]

Reviewing Axonics (NASDAQ:AXNX) and DexCom (NASDAQ:DXCM)

Axonics (NASDAQ:AXNX – Get Rating) and DexCom (NASDAQ:DXCM – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Risk and Volatility Axonics has a beta of 0.39, suggesting that its […]

Axonics, Inc (NASDAQ:AXNX) CFO Sells $120,080 01 in Stock

Axonics, Inc. (NASDAQ:AXNX – Get Rating) CFO Danny L. Dearen sold 2,001 shares of the firm’s stock in a transaction dated Thursday, April 20th. The shares were sold at an average price of $60.01, for a total transaction of $120,080.01. Following the completion of the transaction, the chief financial officer now directly owns 23,993 shares […]

Analysts Set Axonics, Inc (NASDAQ:AXNX) PT at $78 63

Axonics, Inc. (NASDAQ:AXNX – Get Rating) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokers […]

Axonics (NASDAQ:AXNX) versus DexCom (NASDAQ:DXCM) Critical Comparison

Axonics (NASDAQ:AXNX – Get Rating) and DexCom (NASDAQ:DXCM – Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation. Analyst Recommendations This is a summary of recent ratings for Axonics and […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.